GSK and J&J launch €150M VC fund with Index
This article was originally published in Scrip
Pharma giants GlaxoSmithKline and Johnson & Johnson have validated the asset centric investment approach of venture capitalist Index Ventures by cornerstoning a new €150 million fund. The pharma companies have each taken a 25% stake in the exclusively life sciences fund, with longstanding Index limited partners taking up the rest. Crucially, management of the fund will be the responsibility of Index Ventures, the pharma partners will only have an advisory role.